Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm pembrolizumab study in recurrent or metastatic cutaneous squamous cell carcinoma
MOH_2017-06-14_000488Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Merck & Co. Started May 2017; status: active, not recruiting.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on MOH_2017-06-14_000488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-14_000488.